Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07247110 | A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) | PHASE1 | RECRUITING | 250 | — | — | Dec 16, 2025 | Dec 1, 2030 | Jun 3, 2026 | 19 | United States, Australia +5 |
A DLT is defined as the occurrence of protocol-specified toxicities, unless clearly related to disease progression or intercurrent illness.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
| Arm | Type | Description |
|---|---|---|
| MK-4716 Dose Escalation | EXPERIMENTAL | Participants receive MK-4716 at varying dose levels and schedules. |
| MK-4716 + Pembrolizumab | EXPERIMENTAL | Participants will receive MK-4716 + Pembrolizumab |
| MK-4716 + Cetuximab | EXPERIMENTAL | Participants will receive MK-4716 + Cetuximab |
| Name | Type | Description |
|---|---|---|
| MK-4716 | DRUG | Oral administration |
| Pembrolizumab | BIOLOGICAL | Intravenous administration |
| Cetuximab | BIOLOGICAL | Intravenous administration |
Inclusion Criteria: * Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Has a confirmed diagnosis of locally advanced unresectable or metastatic solid tumor * Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Must demonstrate presence of Kirsten...